Gilead Sciences Inc.
0
0
0%

Financials

Income statement

Fiscal date 2024 2023 2022 2021
Total reported revenue 28.8B 27.1B 27.3B 27.3B
Cost of revenue 6.3B 6.5B 5.7B 6.6B
Gross profit 22.5B 20.6B 21.6B 20.7B
Operating expense
Research & development 5.9B 5.7B 5.0B 4.6B
Selling general and admin 6.1B 6.1B 5.7B 5.2B
Other operating expenses
Operating income 10.5B 8.8B 11.0B 10.9B
Non operating interest income
Income 281M
Expense 977M 944M 935M 1.0B
Other income expense -9.1B -1.0B -4.2B -1.6B
Pretax income 690M 6.9B 5.8B 8.3B
Tax provision 211M 1.2B 1.2B 2.1B
Net income 480M 5.6B 4.6B 6.2B
Basic EPS 0.4 4.5 3.7 5.0
Diluted EPS 0.4 4.5 3.6 4.9
Basic average shares 1.2B 1.2B 1.3B 1.3B
Diluted average shares 1.2B 1.2B 1.3B 1.3B
EBITDA 13.6B 11.7B 12.5B 12.3B
Net income from continuing op. 480M 5.6B 4.6B 6.2B
Minority interests 0 52M 26M 24M
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Main market opens in 9 hours 56 minutes

23:33
00:00
09:30
16:00
23:59

Trading Hours (Monday - Friday):

Main market
09:30 - 16:00
All times are displayed in the America/Santiago timezone (-03, UTC-03:00).